Issue 7, 2019

Investigations into the DNA-binding mode of doxorubicinone

Abstract

Cancer treatment is one of the major challenges facing the modern biomedical profession. Development of new small-molecule chemotherapeutics requires an understanding of the mechanism of action for these treatments, as well as the structure–activity relationship. Study of the well-known DNA-intercalating agent, doxorubicin, and its aglycone, doxorubicinone, was undertaken using a variety of spectroscopic and calorimetric techniques. It was found that, despite conservation of the planar, aromatic portion of doxorubicin, the agylcone does not intercalate; it instead likely binds to the DNA minor-groove.

Graphical abstract: Investigations into the DNA-binding mode of doxorubicinone

Supplementary files

Article information

Article type
Paper
Submitted
21 Sep 2018
Accepted
31 Okt 2018
First published
31 Okt 2018

Org. Biomol. Chem., 2019,17, 1992-1998

Investigations into the DNA-binding mode of doxorubicinone

S. S. Tartakoff, J. M. Finan, E. J. Curtis, H. M. Anchukaitis, D. J. Couture and S. Glazier, Org. Biomol. Chem., 2019, 17, 1992 DOI: 10.1039/C8OB02344A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements